Epitan resumes sustained release trial
Tuesday, 06 July, 2004
Melbourne-based EpiTan (ASX:EPT) has resumed its trial of the sustained release implant for tanning drug Melanotan.
The trial is being conducted at Queensland's Clive Berghofer Cancer Research Centre with a new significantly smaller solid injectable. It will be used to determine the optimal dose for the final commercial formulation of Melanotan.
Epitan executive chairman Dr Wayne Millen said the new implant was able to be injected with a 16 gauge needle.
Protein-based therapy helps the body remove harmful cells
Scientists have created a protein-based therapeutic tool that could change the way we treat...
Diabetes changes the structure of our hearts, study finds
Type 2 diabetes directly alters the heart's structure and energy systems, which explains why...
Beta blockers could halt triple negative breast cancer
Researchers have identified a molecular biomarker in triple negative breast cancer tumours which...
